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Transporter  proteins  expressed  in  the  gastrointestinal  tract  play  a  major  role  in the  oral  absorption  of  some
drugs, and their  involvement  may  lead  to drug–drug  interaction  (DDI)  susceptibility  when  given in  com-
bination  with  drugs  known  to  inhibit  gut wall  transporters.  Anticipating  such  liabilities  and predicting  the
magnitude  of the impact  of  transporter  proteins  on  oral  drug  absorption  and  DDIs  requires  quantiﬁcation
of  their  expression  in  human  intestine,  and  linking  these  to data  obtained  through  in  vitro  experiments.
A  quantitative  targeted  absolute  proteomic  method  employing  liquid  chromatography  coupled  to  tan-
dem mass  spectrometry  (LC–MS/MS)  together  with  a quantitative  concatenation  (QconCAT)  strategy  to
provide  proteotypic  peptide  standards  has  been  applied  to quantify  ATP1A1  (sodium/potassium-ATPase;
Na/K-ATPase),  CDH17  (human  peptide  transporter  1; HPT1),  ABCB1  (P-glycoprotein;  P-gp),  ABCG2  (breast
cancer  resistance  protein;  BCRP),  ABCC2  (multidrug  resistance-associated  protein  2; MRP2)  and  SLC51A
(Organic  Solute  Transporter  subunit  alpha;  OST-),  in human  distal  jejunum  (n =  3)  and  distal  ileum
(n  =  1)  enterocyte  membranes.  Previously  developed  selected  reaction  monitoring  (SRM)  schedules  were
optimised  to enable  quantiﬁcation  of  the  proteotypic  peptides  for  each  transporter.  After  harvesting
enterocytes  by  calcium  chelation  elution  and  generating  a total  membrane  fraction,  the  proteins  were
subjected  to proteolytic  digestion.  To  account  for  losses  of  peptides  during  the  digestion  procedure,  a
gravimetric  method  is  also  presented.  The  linearity  of  quantifying  the  QconCAT  from  an  internal  standard
(correlation  coefﬁcient,  R2 = 0.998)  and  quantiﬁcation  of  all target  peptides  in  a pooled  intestinal  quality
control  sample  (R2 ≥  0.980)  was  established.  The  assay  was  also  assessed  for  within  and  between-day
precision,  demonstrating  a <15%  coefﬁcient  of  variation  for all  peptides  across  3  separate  analytical  runs,
over 2  days.  The  methods  were  applied  to obtain  the  absolute  abundances  for all  targeted  proteins.  In
all samples,  Na/K-ATPase,  HPT1,  P-gp  and  BCRP  were  detected  above  the  lower  limit of  quantitation  (i.e.,
>0.2  fmol/g  membrane  protein).  MRP2  abundance  could  be  quantiﬁed  in distal  jejunum  but  not  in  the
distal  ileum  sample.  OST-  was  not  detected  in 2 out  of  3 jejunum  samples.  This  study  highlights  the
utility  of  a QconCAT  strategy  to quantify  absolute  transporter  abundances  in  human  intestinal  tissues.
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1. Introduction
Successful prediction of drug absorption, disposition and
drug–drug interactions (DDIs) is a critical component of drug devel-
opment. Drug transporter proteins functionally expressed in the
plasma membrane of enterocytes can facilitate or hinder drug
absorption and inﬂuence drug disposition in polypharmacy [1].
To estimate the inﬂuence of transporter protein function on drug
absorption, disposition and DDIs, strategies incorporating physio-
logically based pharmacokinetic (PBPK) modelling approaches are
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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sed [2]. Considerable challenges have been encountered in achiev-
ng good predictions when including transporter functionality from
n vitro data within IVIVE-PBPK frameworks [3]. This is, in part,
ased on a lack of high quality data accurately representing trans-
orter abundance levels in a variety of organs. This is pertinent
iven that whole body PBPK models require the incorporation of
rgan-speciﬁc transporter expression including the intestine, that
re typically based on gene expression (i.e., mRNA) or immuno-
lotting analyses [4,5].
Recently, studies have employed LC–MS/MS-based quantitative
argeted absolute proteomic strategies, to quantify the absolute
bundances of transporter proteins in human intestines by an
bsolute quantiﬁcation (AQUA) strategy for generating synthetic
sotope labelled peptides [6–8]. The QconCAT technique is an
lternative method for generating proteotypic isotope labelled pep-
ide standards [9]. An artiﬁcial protein is constructed within an
scherichia coli host vector and expressed, with stable isotope
nrichment of growth media. The extracted artiﬁcial protein is
ubjected to proteolytic digestion strategies to yield equimolar
oncentrations of standard peptides for quantiﬁcation of tar-
et proteins [10]. This approach has recently been applied to
imultaneously quantify several human hepatic cytochrome P450
CYP450) and uridine 5′-diphospho glucuronosyltransferase (UGT)
rug metabolising enzymes and corresponding correlation pro-
les have been highlighted [10]. In addition, the construction of
 transporter protein-speciﬁc QconCAT (‘TransCAT’) has recently
een described [11]. However, the validation of these methods, in
erms of quality control procedures, and their application for quan-
iﬁcation of several transporter proteins by LC–MS/MS has yet to
e reported.
The aim of this study was to validate an LC–MS/MS method to
uantify the absolute abundances of ATP1A1 (sodium/potassium-
TPase; Na/K-ATPase), CDH17 (human peptide transporter 1;
PT1), ABCB1 (P-glycoprotein; P-gp), ABCG2 (breast cancer resis-
ance protein; BCRP), ABCC2 (multidrug resistance-associated
rotein 2; MRP2) and SLC51A (organic solute transporter subunit
lpha; OST-) in human enterocyte membrane preparations using
he TransCAT construct.
. Materials and methods
.1. Materials/reagents
All chemicals and reagents unless speciﬁed were either from
igma–Aldrich (Poole, Dorset, UK), or the supply source can
e obtained from previous studies [10,11]. The details of the
esign, expression in E. coli and puriﬁcation of the TransCAT
ynthesis have been described previously, including that of the
on-naturally occurring peptide (NNOP) peptide calibrator Glu-
ib (EGVNDNEEGFFSAR), incorporated into the construct to enable
uantiﬁcation of the TransCAT [11].
.2. Intestinal Tissue
Human intestinal tissue was obtained after informed consent
rom patients undergoing elective intestinal surgery at Salford
oyal NHS Foundation Trust. Prior ethics committee approval
ad been granted by the North West Research Ethics Committee
12/NW/0306). Patients suffering from inﬂammatory bowel dis-
ase (i.e., Crohn’s disease or ulcerative colitis) and/or known to be
ffected by hepatitis B were excluded from participation. Donor
emographics and recent drug history are provided in Table S1,
upporting Information.nd Biomedical Analysis 110 (2015) 27–33
2.3. Tissue preparation, marker enzyme activity enrichment
Immediately after resection the macroscopically healthy mar-
gins of resected intestinal tissues were opened to expose the
mucosa and were then washed in ice-cold 0.9% NaCl. The tissue
was then transferred in ice-cold oxygenated small bowel ringer
(NaCl (121 mM),  NaHCO3 (25.1 mM),  KHCO3 (1.6 mM), KH2PO4
(0.2 mM),  K2HPO4 (1.2 mM),  CaCl2 (1.2 mM),  MgCl2 (1.2 mM)  and
D-glucose (10 mM)), which had been equilibrated to pH 7.4 by
bubbling with 5% CO2/95% O2. Enterocytes were harvested by
elution from the mucosa by calcium chelation. Brieﬂy, the mucosa
was separated from the underlying bowel wall by blunt dissection
and then placed onto perspex tissue adaptors (constructed by the
Medical Physics Dept, Salford Royal Hospital Trust, Salford, UK),
with 8 or 16 cm2 apertures (typically 16–24 cm2 mucosal surface
area was used, see Table S1, Supporting Information) to expose
the mucosa to chelating solutions. The time from bowel resection
to securing the tissue in adaptors was always less than 1 h. All
solutions used for chelation were made in a base buffer consisting
of NaCl (112 mM),  KCl (5 mM),  HEPES (20 mM),  pH 7.1 (Tris). The
adaptor-secured mucosa was washed twice in base buffer (4 ◦C)
and immersed in a sodium citrate solution (27 mM), pH 7.1 with
a protease inhibitor cocktail at 4 ◦C for 30 min, followed by two
washes in base buffer (4 ◦C). Chelation commenced when the
adaptor-secured mucosa was incubated in an EDTA-buffer (EDTA
(30 mM), heparin (10 U/mL), dithiothreitol (DTT, 1 mM)  and pro-
tease inhibitors), pH 7.1 at 4 ◦C and stirred at 250 rpm for 40 min
at 4 ◦C. The tissue was repeatedly ﬂushed with a 10 mL syringe in
EDTA buffer to harvest chelated enterocytes. The chelated material
was washed by centrifugation twice at 2000 x g (10 min, 4 ◦C). The
enterocytes were stored at −80 ◦C.
The enterocyte pellet was  re-suspended in TSEM buffer
(Tris–HCl (10 mM),  sucrose (250 mM), EGTA (0.1 mM), MgCl2
(0.5 mM),  pH 7.4) at 4 ◦C and homogenised on ice with a Dounce
hand-held homogeniser for a minimum of 75-strokes. The absence
of intact enterocytes was conﬁrmed by microscopy. A previously
described differential centrifugation procedure to obtain a total
membrane (TM) fraction for Caco-2 cells was employed for the
enterocytes in this study [11]. Protein content was determined
using a BCA assay.
The activity of alkaline phosphatase (AP, (EC 3.1.3.1)), a plasma
membrane marker, was utilised to assess enrichment of the TM
fraction compared with the homogenised enterocytes in 7 samples
(donor information supplied in Table S2, Supporting Information).
The liberation of p-nitrophenyl + inorganic phosphate (p-NP + Pi)
by alkaline phosphatase from p-nitrophenylphosphate (p-NPP) is
measured in fresh assay buffer (Glycine (100 mM),  1 mM MgCl2, pH
8.8) in samples containing 10 g protein against a p-NP standard
curve for 60 min  at 37 ◦C. The reaction was stopped by NaOH (1 M)
and was  read on a plate reader at 405 nm for 0.1 s per sample.
2.4. Proteolytic digestion
An adapted in-solution digest was  developed, based on estab-
lished methods [12]. Protein samples (typically 50 g) and the
TransCAT (5 L, 1/10 diluted stock) were suspended in ((NH4)HCO3
(25 mM),  pH 8), denatured with 10% (w/v, ﬁnal volume) sodium
deoxycholate (DOC) and incubated at room temperature for 10 min.
Samples were reduced by DTT (60 mM)  at 56 ◦C for 20 min and sub-
sequently alkylated by iodoacetamide (15 mM)  in the dark at room
temperature for 30 min. The DOC level was reduced to 1% (w/v)
with (NH4)HCO3 (25 mM)  and 1 L of Lys-C (1 g/L) was  added.
The mixture was  incubated at 30 ◦C for 4 hours. Trypsin (2.5 L at
1 g/L; Roche Applied Sciences, Mannheim, Germany) was then
added, and the mixture incubated for 18 h at 37 ◦C. To precipi-
tate the DOC and acidify the digest, triﬂuoroacetic acid was added
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Fig. 1. A schematic of the workﬂow to measure human intestinal transporter protein absolute abundance using a QconCAT method. Part A describes the parallel development
of  the QconCAT (1A) and the human intestinal enterocyte chelation protocol (1B) and directly relates to Sections 2.2 and 2.3 in this article. Part B describes sample digestion
and  preparation for LC–MS/MS, where IAA is iodoacetamide. The simultaneous digestion of the extracted QconCAT peptide containing the isotope labelled standards and the
TM  fraction (post BCA protein assay), typically 50 g, from the chelated intestinal enterocytes is performed (2), relating to Section 2.4 in this article. During the digestion
procedure, prior to loading the digested sample into a vial for LC–MS/MS, peptide losses are determined gravimetrically (see Supporting Information). The digested peptides
containing the sample and isotope labelled peptide standards are combined with a synthetic unlabelled calibrator Non-Naturally Occurring Peptide (NNOP) of known
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0.1–0.5%, v/v) to achieve the optimal pH of 3, and was chilled at 4 ◦C
or 30 min. After two 14,000 × g spins, the supernatant containing
he peptides was removed and evaporated by vacuum centrifuga-
ion with adjustment to 3% acetonitrile and stored at −20 ◦C.
.5. Gravimetric determination of peptide content
To account for losses of peptides through the digestion proce-
ure, i.e.,  the DOC precipitation stage and any additional losses
esulting from non-speciﬁc binding to preparatory/LC–MS/MS
ubes and during pipetting, a gravimetric method using an ana-
ytical balance was developed to determine the protein content
ntering the LC system. The protein content relates the abundance
n fmol of the target peptide in the digest to abundances per g in
he ‘Protein’ matrix under study (fmol/g). In order to derive pep-
ide mass by gravimetric means, there are a series of instances in
hich sample tubes and their contents mass (g) and volumes are
easured (see Supporting Information).
.6. LC–MS/MS analysis
A typical mixture of: digested sample, standard (QconCAT) and
NOP (calibrator peptide) (‘the sample’) was prepared as follows:
8 L of digested membrane protein and standard with 2 L of
tock NNOP/Glu-Fib (25 pmol/L) which was diluted 1/100,000 in
% acetonitrile to provide a ﬁnal concentration of 0.238 fmol/L
fter correction for Glu-Fib stock purity (95%).
Samples (8 L injection) were analysed by LC–MS/MS as pre-
iously described [10,11]. Peptides were eluted with a gradient article). Part C describes obtaining co-elution proﬁles (labelled and unlabelled) for
 into the equation in this ﬁgure. Any term in this ﬁgure enclosed with apostrophes
of 3–60% acetonitrile over 40 min, followed by a ramp to 95%
acetonitrile for 5 min, then a return to starting conditions for 10 min
to re-equilibrate the system. In a departure from the previous stud-
ies [10,11], Skyline version 2.5.0.6079 was  used (MacCross Lab
Software, Seattle, USA). The selected transitions are given in Table
S3 in the Supporting Information. For each transition, the dwell
time was set manually at 0.15 s.
2.7. Method validation
To validate the methods for quality control, linear regression
analysis was  employed to evaluate; (1) the linearity of the calibra-
tor NNOP, and, (2) the sample peptides in relation to the NNOP
dilution factor [10]. To assess NNOP linearity, a calibration curve
was prepared using the synthetic ‘light’ Glu-Fib and a pre-digested
TransCAT construct to calculate the light to heavy peak area under
the curve ratio over a 100-fold range. A pool of 3 digested sam-
ples was generated to evaluate sample peptide to QconCAT dilution
factor linearity in a similar manner to that previously described
for CYP3A4 and CYP3A5 [10]. Assay precision was  assessed in 5
samples with 3 separate injections per sample, spanning 2 days for
each peptide. The within-day (intra-day) and between-day (inter-
day) precision was  assessed in two  separate runs for 5 samples. The
impact of inter-operator differences when manually evaluating the
co-elution proﬁle boundaries that enable Skyline to calculate the
light-to-heavy peak area of selected peptides was also assessed.
Two independent operators performed this analysis.
Transporter abundances were determined from TransCAT-
derived proteotypic standards as previously described for CYP
30 M.D. Harwood et al. / Journal of Pharmaceutical and Biomedical Analysis 110 (2015) 27–33
Fig. 2. Histological assessment of enterocyte elution by the EDTA chelation method in haematoxylin and eosin (H & E) stained human distal ileum. Sections were cut at a
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tructure denoted by ‘X’. (B) The process of enterocyte shedding, denoted by ‘Y’ as
nderlying lamina propria layer after EDTA incubation, denoted by Za and Zb.
nd UGT enzymes [10], and the equation is given in Fig. 1. The
atios of native (light) and standard (heavy) selected transitions
or each peptide were calculated in Skyline. The ‘Protein’ term
n Equation S14 (Supporting Information) reﬂects the gravimet-
ically determined protein content (Supporting Information) and
ot the nominal protein content entering the digestion procedure.
ll results are given as mean abundance (fmol/g  total membrane
rotein) ± standard deviation.
. Results and discussion
The aim of this study was to optimise and validate an LC–MS/MS-
ased method to quantify the absolute abundance of 6 key
embrane transporter proteins in human intestinal samples with
sotope labelled proteotypic peptides generated using a QconCAT
trategy [11]. A schematic to describe the workﬂow of this study is
rovided in Fig. 1.
.1. Harvesting intestinal enterocytes and marker enzyme
nrichment
A calcium chelating agent, EDTA, was used to liberate the
nterocytes from the basal lamina propria by securing the stripped
ntestinal mucosa in specialised adaptors to maximise EDTA expo-
ure of the luminal mucosal surface. A histological inspection of
istal ileal mucosa (Fig. 2) showed that enterocytes were removed
rom the underlying lamina propria layer after elution. The TM pro-
ein yield for the distal jejunum (n = 3) was 22.37 ± 4.57 g/cm2 and
or the single distal ileum, 16.61 g/cm2, considerably lower val-
es than those obtained after mucosal scraping [13]. This is likely to
esult from the scraping technique sampling the underlying inter-
titium.
Enrichment in the activity of a plasma membrane marker, alka-
ine phosphatase, was assessed in the starting total protein and (A) Distal ileum not subjected to EDTA (control), with an intact enterocyte-villus
lt of EDTA incubation. (C) and (D) The complete removal of enterocytes from the
TM fraction. A 3.64 ± 1.74-fold increase in the activity of alkaline
phosphatase in the TM fraction relative to the total protein
homogenate (n = 7) conﬁrmed an increase in the purity of the TM
with plasma membrane components (Fig. 3).
3.2. LC–MS/MS analysis
Upon LC–MS/MS analysis, only one peptide for each transporter
protein was suitable for quantiﬁcation and can be used, to vary-
ing extents, for quantiﬁcation in other mammalian species used as
preclinical models in drug development (Table 1). Peptide selection
was further based on a combination of in silico selection criteria;
the identiﬁcation of the 3 transitions that gave the highest signal
intensity using synthesised sequence-equivalent unlabelled pep-
tides (Maxi SpikeTides; JPT Peptide Technologies GmbH, Berlin,
Germany), and identifying previously optimised product ion tran-
sitions in intestinal TM digests. A SRM method was  developed to
simultaneously detect three singly charged product ions of each of
the selected peptides in a single analytical run (Table S3, Suppor-
ting Information). For the NNOP (Glu-Fib) and HPT1, two  product
ion transitions were of sufﬁcient intensity to develop the ﬁnalised
SRM method.
3.3. Method validation
The linearity of measurement of the QconCAT concentration
from the co-elution of the internal QconCAT calibrator peptide
NNOP (EGVNDNEEGFFSAR) was established over a greater than
100-fold range of QconCAT to NNOP ratio in the assay mix, with
R2 close to 1 (Figure S1a, Supporting Information). The linearity of
peptide abundances in a pooled sample of 3 intestinal TM digests
was established over a 14-fold range (R2 ≥ 0.980) (Figure S1b,
Supporting Information). The lower limit of quantitation (LLOQ)
was determined in the biological matrix at the lowest protein
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Fig. 3. Alkaline phosphatase activity enrichment in the TM fraction compared to the original starting homogenate total protein fraction. The assay was performed with
proteins from jejunum (n = 3), ileum (n = 2) and distal colon (n = 2) during enterocyte chelation optimisation experiments (see Table S2 in Supporting Information).
Table 1
Species speciﬁcity of the selected transporter protein proteotypic peptides. A 100% agreement in sequence identity between the native protein and the proteotypic peptide
is  denoted by a check/tick mark (
√
).
Transporter Peptide sequence Homo sapiens Macaca fascicularis Canis familiaris Mus  musculus Rattus norvegicus
Na/K-ATPase IVEIPFNSTNK
√ √ √ √ √
HPT1 AENPEPLVFGVK
√
X X X X
P-gp AGAVAEEVLAAIR
√ √ √ √ √
MRP2 LVNDIFTFVSPQLLK
√ √
X X X
c
a
n
v
w
e
e
s
r
r
r
e
T
P
t
o
e
oBCRP VIQELGLDK
√ √
OST-  YTADLLEVLK
√
X 
ontents injected (0.23 g) as 0.2 fmol/g. Within-day (intra-day)
nd between-day (inter-day) precision was assessed in 5 intesti-
al TM digests. The precision (coefﬁcient of variation of the mean
alues) over 3 analytical runs between 2 separate days was <15%,
ithin current FDA bio-analytical guidelines [14]. The relative
rrors (RE) within-day and between-day were <±15%, with the
xception of MRP2 and OST- that were below the LLOQ in some
amples and displayed RE <±20% (Table 2).
Previous characterisation of the TransCAT [11] using the
eported dual enzyme digestion strategy conﬁrmed proteolysis
eached steady state. Another study using the same protocol
eported the same result [10]. Assessment of the stability and recov-
ry of peptides is also required by FDA guidelines on bioanalytical
able 2
recision (coefﬁcients of variation, CV, %) analysis is provided for transporter pro-
eins  in human intestinal total membrane (TM) digests (n = 5) over 3 sample runs,
n 2 separate days. Within and between-day differences are provided as relative
rrors (RE, %) in two  separate sample runs.
Protein All runs Within-day Between-day
Precision (%) RE (%) RE (%)
TransCAT 5.2–11.3 5.3 to 10.8 −8 to 12.5
Na/K-ATPase 5.4–12.7 6.7 to 13.1 −3.5 to 14.5
HPT1 1.4–11.4 −2.7 to 7.3 −10.4 to 10.2
P-gp 2.5–14.7 0.9 to 12.8 −2 to 13.9
MRP2a 4.3–10.3 4.8 to 18.6 −7.5 to 3.8
BCRP 2.3–8.0 −0.2 to 9.9 −11 to 10.3
OST- 4.7–11.5 −8.7 to 15.4 −10.3 to 6.1
a Precision for one of the samples was based on two runs, as run 3 represented an
utlier for MRP2.X X X
X X X
method validation. Although these were not covered, steps were
taken to limit known causes of degradation of peptides by analysing
within a short time of preparation and limiting the number of
freeze–thaw cycles to less than 3. Also, peptide loss in the assay
was estimated using the developed gravimetric method. For trans-
porter proteins, establishing accuracy in an AQUA or QconCAT assay
is difﬁcult to implement due to absence of standard reference
materials comprising protein standards of known concentration
in suitable biological matrices and has only been demonstrated
in a single study for proteo-liposomes containing P-gp [15], but is
not routinely performed. However, the optimal approach to deter-
mine accuracy is to run biological matrices under study against
samples containing a known concentration of the puriﬁed target
protein. Collectively, it is the lack of available standards of known
concentrations, and the requirement for an internal standard to
quantify the QconCAT concentration, that creates a signiﬁcant
challenge to implement the accuracy strategies employed in the lit-
erature, especially for drug transporter proteins. Recently, accuracy
measurements for a QconCAT construct have been performed for
CYP3A4 and CYP3A5 in commercially available liver microsomes, in
which the enzyme abundances were measured by immunoblotting
and ELISA [10]. Thus, given the assumption that there is equimolar
release of standard peptides during overnight digestion, accurate
stoichiometric determination of light and heavy peak signal inten-
sity should permit peptide quantiﬁcation with sufﬁcient accuracy.The potential loss of peptides during the DOC precipitation step,
or due to non-speciﬁc binding to liquid handling equipment, was
accounted for by a gravimetric procedure based on the masses
of sample tubes, peptide solutions and precipitates. The total TM
32 M.D. Harwood et al. / Journal of Pharmaceutical and Biomedical Analysis 110 (2015) 27–33
Fig. 4. Absolute abundances of transporter proteins in human distal jejunum and ileum TM fractions. (A) The transporter protein abundances in distal jejunum from 3 donors,
measured in 3 separate analytical runs. (B) The transporter abundances in an ileum sample from a single donor, measured in 3 separate analytical runs. Data are expressed
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as  below the limit of quantiﬁcation (<0.2 fmol/g membrane protein). For OST-
uantiﬁcation for the other two  biological samples.
rotein entering the digest was 50 g for all samples of which 32 g
32.01 ± 3.37 g peptide, n = 4) was recovered giving an estimated
ecovery of 64%, which was applied as a correction factor to all
eptide abundances.
Inter-operator differences in abundance quantiﬁcation were
ssessed between 2 independent analysts for 104 co-elution pro-
les (7 peptides in 5 samples). In >99% of cases, the abundance
alues determined by each operator were within a pre-deﬁned
hreshold of 1.25-fold difference between-operators. These quality
ontrol steps are rarely performed within the drug metabolising
nzymes and transporters proteomics ﬁeld and are essential for
omparability of work over a longer period of time and between
ifferent laboratories employing similar techniques.
.4. Application of methods
This study provides a validated LC–MS/MS method using
conCAT derived proteotypic standard peptides to measure the
bundances of 6 key drug transporter proteins in human distal
ejunum (n = 3) and distal ileum (n = 1), adding to the limited data
urrently available that quantiﬁes the absolute abundance of trans-
orter proteins in the human intestine using targeted proteomic
echniques [6–8]. The advantage that the QconCAT technology pro-
ides over conventional QTAP techniques is the ability to use one
tandard for a host of target proteins, making it more amenable to
imultaneous multiplexed quantitative analysis, in addition to then abundance of the transporter protein. BLQ denotes that the protein abundance
for the jejunum is based on a single donor as its abundance was below the limit of
sustainability of the expressed standard and transferability of the
QconCAT vector providing an unlimited source of standard pep-
tides in different laboratories, for lower cost when analysing ≥10
proteins [16].
The abundances of the 6 quantiﬁed transporter proteins are
shown in Fig. 4. The basal membrane marker protein Na/K-ATPase
showed a considerably higher membrane expression than the
other proteins under study. The cadherin-like peptide transporter
that also possesses pharmacological relevance [17], HPT1, was
selected for analysis as it was anticipated to be a highly abundant
apical/lateral membrane marker protein in the intestine, which
was conﬁrmed. Of the apical efﬂux transporter proteins stud-
ied in the distal jejunum, the rank order of mean expression is
BCRP > P-gp > MRP2, similar to the rank observed in duodenal sam-
ples in which the absolute abundance was  determined with an
S-tagging quantitative immunoblot approach [13]. Yet, in a targeted
proteomic strategy, MRP2 was shown to possess the highest abun-
dance compared to P-gp and BCRP [6–8]. In our single distal ileum
sample, MRP2 abundance was below the limit of quantiﬁcation.
The mean absolute levels of P-gp and BCRP in jejunum differ by
approximately 3 and 7-fold respectively, as does the rank order of
expression for P-gp, BCRP and MRP2 between this study and stud-
ies centred at The University of Greifswald [6–8]. These differences
may  arise from inherently different biological expression between
the tissues, or from differences in the techniques applied to obtain
abundances.
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[M.D. Harwood et al. / Journal of Pharmaceu
The OST- subunit forms a dimeric molecule with the OST-
ubunit, which is functionally expressed in the basal membrane
f enterocytes and has been shown to participate in endogenous
ompound and digoxin transport [18,19]. The OST- subunit was
xpressed at relatively low levels, and could not be detected in 2 of
 jejunum samples. The assay may  ﬁnd greater utility when applied
o terminal ileum where OST-/ is likely to be expressed at higher
evels due to its involvement in bile acid reabsorption.
The inﬂuence on recent drug administration should also be con-
idered when determining transporter abundances. The 4 donors
ad all been administered a variety of drugs in the recent past which
ay  have inﬂuenced transporter expression (Table S1, Supporting
nformation). Characterising protein abundances in tissues origi-
ating from a diseased population is critical to generating PBPK
odels in clinical sub-populations for which the drugs are primar-
ly indicated.
. Conclusion
This study has optimised LC–MS/MS targeted proteomic meth-
ds for quantifying drug transporter protein absolute abundance
sing a QconCAT strategy. The methods were applied to mea-
ure Na/K-ATPase, HPT1, P-gp, BCRP, MRP2 and OST- in eluted
uman enterocyte total membrane fractions. This study provides
he basis to develop further SRM methods for quantiﬁcation of
umerous other proteins of pharmacological relevance in many
ifferent organs.
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